Evaluation of OnabotulinumtoxinA Treatment in Patients with Concomitant Chronic Migraine and Temporomandibular Disorders

Creative Commons License

Kocaman G., Kahraman N., Gurkan Koseoglu B., Bilgic B., Matur Z., Ertas M., ...Daha Fazla

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.55, sa.4, ss.330-336, 2018 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.5152/npa.2017.19257
  • Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.330-336
  • Anahtar Kelimeler: Temporomandibular disorders, headache, onabotulinumtoxinA, chronic migraine, TOXIN TYPE-A, PLACEBO-CONTROLLED PHASE, BOTULINUM-TOXIN, DOUBLE-BLIND, HEADACHE, PAIN, SYMPTOMS, RELIABILITY, POPULATION, PREVALENCE
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Bezmiâlem Vakıf Üniversitesi Adresli: Evet

Özet

Introduction: Migraine and temporomandibular disorders (TMD) are both common diseases and TMD are reported as a risk factor in migraine progression. OnabotulinumtoxinA is used in the treatment of chronic migraine (CM), and also has a potential role in TMD treatment. In this study, it is aimed to compare the efficacy of onabotulinumtoxinA treatment in CM patients with and without TMD.